Skip to content
sellModerate cluster of 210b5-1 plan

Jacob Chacko sold $1.1M of ORIC

PRESIDENT AND CEO at Oric Pharmaceuticals, Inc.. 87,539 shares at an average of $12.04, traded Sep 30, 2025, filed Oct 2, 2025.

Warning score
43
Value
$1.1M
87,539 shares
Holdings after
568,880
-13% from before
From 52-week low
+182%
low $4.26, close $12.00
From 52-week high
-4%
high $12.54, as of Sep 30, 2025

Score components

  • Role
    CEO
    +25
  • Trade size
    $1.1M at market
    +25
  • Share of holdings sold
    Sold 13% of holdings
    +5
  • Cluster
    2 insiders selling within 14 days
    +8
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

ORICOct 9, 2026 · close 11.99
Since filing Oct 2, 2025: +5.9%SPY +17.6% · excess -11.7%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001608936-25-000008, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Sep 30, 2025SOpen-market sale
Common Stock10b5-1
-34,538$12.01$415k621,881Oct 2, 2025
Oct 1, 2025SOpen-market sale
Common Stock10b5-1
-53,001$12.05$639k568,880Oct 2, 2025

Related signals

Other insiders at Oric Pharmaceuticals, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
2Weak
ORICsell 210b5-1
Oric Pharmaceuticals, Inc.
Richard A. Heyman
director
$87k
6,700 shares
-16%
12Weak
ORICsell 210b5-1
Oric Pharmaceuticals, Inc.
Dominic Piscitelli
Chief Financial Officer
$181k
13,400 shares
-16%
0Weak
ORICsell 210b5-1
Oric Pharmaceuticals, Inc.
Dominic Piscitelli
Chief Financial Officer
$8,103
600 shares
-1%
9Weak
ORICsell10b5-1
Oric Pharmaceuticals, Inc.
Richard A. Heyman
director
$80k
6,700 shares
-15%
39Weak
ORICsell 3
Oric Pharmaceuticals, Inc.
Jacob Chacko
PRESIDENT AND CEO
$302k
33,374 shares
-5%
30Weak
ORICsell 3
Oric Pharmaceuticals, Inc.
Pratik S Multani
Chief Medical Officer
$97k
10,720 shares
-14%
37Weak
ORICsell 3
Oric Pharmaceuticals, Inc.
Dominic Piscitelli
Chief Financial Officer
$97k
10,720 shares
-14%
30Weak
ORICsell 210b5-1
Oric Pharmaceuticals, Inc.
Jacob Chacko
PRESIDENT AND CEO
$462k
37,461 shares
-7%
11Weak
ORICsell 210b5-1
Oric Pharmaceuticals, Inc.
Dominic Piscitelli
Chief Financial Officer
$160k
11,000 shares
-19%
43Moderate
ORICsell 210b5-1
Oric Pharmaceuticals, Inc.
Jacob Chacko
PRESIDENT AND CEO
$1.3M
125,000 shares
-16%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Jacob Chacko sold $1.1M of ORIC | InsiderTell